These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31935278)

  • 1. Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
    Gottschalk A; Glauche I; Cicconi S; Clark RE; Roeder I
    Blood; 2020 Mar; 135(10):766-769. PubMed ID: 31935278
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
    Richter J; Lübking A; Söderlund S; Lotfi K; Markevärn B; Själander A; Stenke L; Deneberg S; Ahlstrand E; Myhr-Eriksson K; Panayiotidis P; Gedde-Dahl T; Žáčková D; Mayer J; Olsson-Strömberg U; Mahon FX; Saussele S; Hjorth-Hansen H; Koskenvesa P
    Leukemia; 2021 Aug; 35(8):2416-2418. PubMed ID: 33589755
    [No Abstract]   [Full Text] [Related]  

  • 3. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib is still recommended for frontline therapy for CML.
    Hantel A; Larson RA
    Blood Adv; 2018 Dec; 2(24):3648-3652. PubMed ID: 30587493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
    Shah NP
    J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
    Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
    BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concept of treatment-free remission in chronic myeloid leukemia.
    Saußele S; Richter J; Hochhaus A; Mahon FX
    Leukemia; 2016 Aug; 30(8):1638-47. PubMed ID: 27133824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
    Menif S; Ben Youssef Y; Bellaaj H; Ben Lakhal R; Laatiri A
    Tunis Med; 2017 Dec; 95(12):229-231. PubMed ID: 29878287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.
    Kunbaz A; Eskazan AE
    Expert Rev Hematol; 2019 Jul; 12(7):477-480. PubMed ID: 31166812
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
    Clark RE
    Curr Hematol Malig Rep; 2019 Dec; 14(6):507-514. PubMed ID: 31701369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.
    Egan D; Radich J
    Am J Hematol; 2016 Jul; 91(7):742-6. PubMed ID: 27059166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response-related predictors of survival in CML.
    Hanfstein B; Müller MC; Hochhaus A
    Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
    Takahashi N
    Rinsho Ketsueki; 2016; 57(10):1956-1961. PubMed ID: 27725593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
    Erba HP
    Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".
    Breccia M; Alimena G
    Leuk Res; 2012 Dec; 36(12):1498-9. PubMed ID: 23031556
    [No Abstract]   [Full Text] [Related]  

  • 18. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
    Haznedaroğlu İC; Kuzu I; İlhan O
    Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Dose Modification of TKI Therapy in CML?
    Copland M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):337-345. PubMed ID: 31197525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.